Fragile X syndrome in the largest world clustering. I. Genetic epidemiology and founder effect outline

• Published in: American journal of medical genetics. Part A 2024-05, Vol.194 (5), p.e63523-n/a
• Main Authors: Ramírez‐Cheyne, Julián, López, Diana, Payán‐Gómez, César, Arcos‐Burgos, Mauricio, Saldarriaga, Wilmar
• Format: Article
• Language: English
• Subjects: Colombia; Epidemiology; exomic sequencing; Female; FMR1; FMR1 gene; FMR1 protein; Founder Effect; Fragile X Mental Retardation Protein - genetics; Fragile X syndrome; Fragile X Syndrome - epidemiology; Fragile X Syndrome - genetics; Genotypes; Haplotypes; Humans; Intellectual disabilities; Male; Molecular Epidemiology; Mutation; population isolates; Quality of life; Single-nucleotide polymorphism; Trinucleotide Repeat Expansion
• ISSN: 1552-4825; 1552-4833; 1552-4833
• DOI: 10.1002/ajmg.a.63523

The FMR1 5′ regulation gene region harbors a CGG trinucleotide repeat expansion (CGG‐TRE) that causes Fragile X syndrome (FXS) when it expands to more than 200 repetitions. Ricaurte is a small village in southwestern Colombia, with an FXS prevalence of 1 in 38 men and 1 in 100 women (~100 times higher than the worldwide reported prevalence), defining Ricaurte as the largest FXS cluster in the world. In the present study, using next‐generation sequencing of whole exome capture, we genotype 55 individuals from Ricaurte (49 with either full mutation or with premutation), four individuals from neighboring villages (with either the full mutation or with the premutation), and one unaffected woman, native of Ricaurte, who did not belong to any of the affected families. With advanced clustering and haplotype reconstruction, we modeled a common haplotype of 33 SNPs spanning 83,567,899 bp and harboring the FMR1 gene. This reconstructed haplotype was found in all the men from Ricaurte who carried the expansion, demonstrating that the genetic conglomerate of FXS in this population is due to a founder effect. The definition of this founder effect and its population outlining will allow a better prediction, follow‐up, precise and personalized characterization of epidemiological parameters, better knowledge of the disease's natural history, and confident improvement of the clinical attention, life quality, and health interventions for this community.